We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Method Provides Accurate Quantitative Measurement of Protein Biomarkers

By LabMedica International staff writers
Posted on 06 May 2009
A protein biomarker assay methodology provides reproducible, quantitative measurement of protein expression in formalin-fixed paraffin embedded (FFPE) tissue samples.

Formalin fixation of tissue samples that are subsequently embedded in paraffin is the gold standard for biopsy and surgical tissue preservation. However, proteins within the tissue samples are heavily cross-linked as a result of the formalin fixation and options for analyzing them have been limited.

NextGen Sciences (Ann Arbor, MI, USA), together with Expression Pathology, Inc. (Rockville, MD. USA), developed a new protein assay methodology. Expression Pathology's liquid tissue reagents and protocols are used for sample preparation and solubilization of the entire protein content from standard FFPE tissue. The solubilized proteins are assayed by NextGen Sciences using multiple reaction monitoring (MRM), a method for quantitation of proteins using mass spectrometry. The two companies began collaborating in June 2008, and demonstrated the utility of the FFPE MRM assay methodology by measurement of the Her2 protein, which has become an important marker for breast cancer diagnosis and therapy.

"The development of this assay shows that FFPE tissue can be used for direct measurement of clinically important protein biomarkers by mass-spectrometry-based protocols," said Michael Pisano, CEO, NextGen Sciences. "As MRM assays can be multiplexed, we have the potential to develop assays where multiple proteins are measured simultaneously, for example cancer therapy targets or cell signaling pathway proteins."

Related Links:

NextGen Sciences
Expression Pathology



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN

Latest Molecular Diagnostics News

Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
06 May 2009  |   Molecular Diagnostics

Urine Test Diagnoses Early-Stage Prostate Cancer
06 May 2009  |   Molecular Diagnostics

New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
06 May 2009  |   Molecular Diagnostics